X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the partnership, Worldwide Clinical Trials will support the Company’s planned Phase 1 trial with ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor in development for the treatment of chemotherapy-induced peripheral neuropathy (CIPN).
Lead Product(s): ART26.12
Therapeutic Area: Neurology Product Name: ART26.12
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Worldwide Clinical Trials
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 08, 2024
Details:
ART26.12 is a potential first-in-class orally administered Fatty Acid Binding Protein 5 (FABP5) inhibitor drug, initially under development for the prevention of chemotherapy-induced peripheral neuropathy.
Lead Product(s): ART26.12
Therapeutic Area: Neurology Product Name: ART26.12
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
ART27.13 (synthetic cannabinoid) is a highly potent, peripherally restricted synthetic, dual G-Protein Couple Receptor agonist believed to target the cannabinoid receptors CB1 and CB2, which has the potential to increase appetite and food intake.
Lead Product(s): ART27.13
Therapeutic Area: Nutrition and Weight Loss Product Name: ART27.13
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
ART27.13 (synthetic cannabinoid)is a highly potent, peripherally restricted synthetic, dual G-Protein Couple Receptor agonist believed to target the cannabinoid receptors CB1 and CB2 , which has the potential to increase appetite and food intake.
Lead Product(s): Cannabinoid
Therapeutic Area: Nutrition and Weight Loss Product Name: ART27.13
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2023
Details:
ART26.12, is a selective inhibitor of FABP5 for the prevention and/or treatment of chemotherapy induced Peripheral Neuropathies, for which there are no regulatory approved medicines.
Lead Product(s): ART26.12
Therapeutic Area: Psychiatry/Psychology Product Name: ART26.12
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2022
Details:
The mild to moderate adverse events observed in CAReS that have been attributed to ART27.13 (synthetic cannabinoid) required no dose reductions or terminations and many of the adverse events required no medical intervention at all.
Lead Product(s): Synthetic Cannabinoid
Therapeutic Area: Nutrition and Weight Loss Product Name: ART27.13
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2022
Details:
In the prevention studies, ART26.12 also minimized the acute weight loss caused by oxaliplatin. These results support further development of ART26.12 in neuropathy associated with chemotherapy and other neuropathies.
Lead Product(s): ART26.12
Therapeutic Area: Oncology Product Name: ART26.12
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2022
Details:
ART26.12, the Company’s lead fatty acid binding protein 5 (FABP5) inhibitor, may be particularly useful for the treatment of specific cancers, neuropathic and nociceptive pain, and anxiety disorders.
Lead Product(s): ART26.12
Therapeutic Area: Oncology Product Name: ART26.12
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Details:
Artelo believes the Trinity College research initiative will refine and expand the Company’s understanding of the role of certain FABP inhibitors and could conceivably translate into multiple compounds tailored to specific cancers from Artelo’s library of compounds.
Lead Product(s): ART26.12
Therapeutic Area: Oncology Product Name: ART26.12
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Trinity College Dublin
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 28, 2022
Details:
ART12.11 is a proprietary cocrystal composition of cannabidiol known to exhibit solid polymorphism, or the ability to manifest in different forms, develop treatments for people living with cancer, pain, and neurological conditions.
Lead Product(s): Synthetic Cannabinoid
Therapeutic Area: Nutrition and Weight Loss Product Name: ART27.13
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
